Full Press Release Details
BrainStorm Cell Therapeutics
Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm to submit a Biologics License Application
(BLA) to the U.S. Food and Drug Administration (FDA) for NurOwn for the treatment of ALS
New clinical analyses reinforce the conclusions
from NurOwn's Phase 3 clinical trial
Conference call and webcast at 8:00 a.m. Eastern
NEW YORK, August 15, 2022 - BrainStorm
Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today
announced financial results for the second quarter ended June 30, 2022, and provided a corporate update. The company also announced its
decision to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration for NurOwn for the treatment
of amyotrophic lateral sclerosis (ALS).
BrainStorm announces decision to submit a BLA
to the FDA for NurOwn for the treatment of ALS
"Brainstorm Cell Therapeutics is at a pivotal
moment as a company as we finalize the regulatory filing for NurOwn in the treatment of ALS. The continued analysis and the
feedback received from the many scientific presentations of NurOwn's Phase 3 data have uncovered key insights that furthered
our understanding of the product mechanism of action and therapeutic potential and strengthened the conclusions of NurOwn's
efficacy," said Chaim Lebovits, Chief Executive Officer. "After carefully considering these learnings, the totality of the
evidence from NurOwn's clinical studies, and the feedback received from key opinion leaders and the broader ALS community,
we will submit a Biologics License Application to the FDA. We are deeply grateful to the ALS clinical experts, members of the ALS community
and faithful investors for their contribution to the development of NurOwn and what it may mean to those living with ALS.
Their contributions and commitment made our current progress possible and continue to inspire us as we prepare for the considerable work
ahead. We intend to provide additional updates upon learning whether the FDA files our BLA submission."
New clinical analyses strengthen the conclusions
from NurOwn's Phase 3 clinical trial
A correction was made to the Muscle and Nerve publication
from December 2021 describing the results of NurOwn's Phase 3 clinical trial in ALS following new clinical analyses which
strengthen the Company's original conclusions from the trial. The correction results in a statistically significant treatment difference
(p=0.050) of more than 2 points for an important secondary endpoint, average change from baseline in ALSFRS-R, in the pre-specified efficacy
subgroup of participants with a baseline score of at least 35. Analyses reported in the original publication utilized an efficacy model
that unintentionally deviated from the trial's pre-specified statistical analysis plan by erroneously incorporating interaction
terms between the subgroup and treatment. The newly published results, which includes supporting information to the publication, employ
the efficacy model as pre-specified in the trial's statistical analysis plan, correcting the analyses. The correction also relates
to the other subgroup analyses published for this endpoint, demonstrating that all subgroups with ALSFRS-R baseline scores of at least
26 to 35 showed a statistically significant benefit following treatment with NurOwn (p 0.050) on this secondary endpoint.
Other Second Quarter 2022 and Recent Highlights
for the Second Quarter Ended June 30, 2022
Cash, cash equivalents,
and short-term bank deposits were approximately $12.2 million as of June 30, 2022, compared to $18.4 million as of March 31,
Research and development
expenses for the three months ended June 30, 2022, and 2021 were approximately $5.1 million and $3.6 million, respectively.
General and administrative
expenses for the three months ended June 30, 2022, and 2021 were approximately $2.5 million.
Net loss for the three
months ended June 30, 2022, was approximately $7.0 million, as compared to a net loss of approximately $6.3 million for the three
months ended June 30, 2021.
Net loss per share for
the three months ended June 30, 2022, and 2021 was $0.19 and $0.17, respectively.
Conference Call and Webcast
August 15, 2022, at 8:00 a.m. Eastern
Participant Numbers:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 955552
Webcast URL: https://bit.ly/3cXwQkt
Those that wish to listen
to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 46290
The NurOwn technology platform (autologous
MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative
disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and
differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete
high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory
cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights
to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through
an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food
and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm
has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration
of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm
completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells
in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).
Safe-Harbor Statement
in this announcement other than historical data and information, including statements regarding future BLA submission, constitute "forward-looking
statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially
from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would,"
"could," "will," "expect," "likely," "believe," "plan," "estimate,"
"predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability
to continue as a going concern, BrainStorm's plan to submit a BLA for NurOwn to the FDA, prospects that the FDA will accept
BrainStorm's BLA for NurOwn for filing and review, prospects that the FDA does not view BrainStorm's NurOwn
product candidate to have demonstrated adequate safety or effectiveness, prospects
for future regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs
and research, regulatory and personnel issues, development of a global market for BrainStorm's products, if approved, and services,
the ability to secure and maintain research institutions to conduct BrainStorm's clinical trials, the ability to generate significant
revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other
neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents
that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from
infringement by third parties, health reform legislation, demand for our services, currency exchange rates and product liability claims
and litigation; the impacts of the COVID-19 pandemic and additional strains of COVID-19 or any other health epidemic on our clinical
trials, supply chain, and operations; potential delays in any planned or anticipated review or interactions with the FDA due to disruptions
at, or inadequate funding of, the FDA; the impact of global economic and political developments on our business, including rising inflation
and capital market disruptions; the current conflict in Ukraine, economic sanctions and economic slowdowns or recessions that may result
from such development; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q
available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance